Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Controlin Healthy Beagle Dogs with Normal Gluco-Homeostasis

[摘要] References(35)Sitagliptin is a dipeptidyl peptidase-4 inhibitor aimed at treating Type 2 diabetesmellitus (T2DM) and T1DM, by increasing blood levels of Glucagon-like peptide 1 (GLP-1)and insulin. The objective of this preliminary study is to characterize Sitagliptin’sability for glycemic control, in healthy dogs under an oral glucose tolerance test (OGTT)environment. Overall, Sitagliptin did not result in any significant changes to temporalglucose and insulin concentrations. However, a ~55% increase in median total GLP-1AUC0�?120min was observed, as compared to baseline control in healthy dogs(n=5), thus indicating a similar mode of action of Sitagliptin between healthy dogs andhumans. Future studies to validate the use of Sitagliptin with dogs suffering from insulinindependent diabetes are warranted.

[学科分类] 兽医学

[关键词] canine;GIP;GLP-1;glucose;insulin;Sitagliptin